In vivo Imaging and Therapeutic Treatments in an Orthotopic Mouse Model of Ovarian Cancer
August 17th, 2010
35.2K views
Orthotopic animal models of ovarian cancer replicate better human disease and therefore enhance our understanding of cancer progression and tumor response to therapy. A mouse model receives an intrabursal injection of luciferase-expressing ovarian tumor cells. Treatment is administered via oral gavage. Tumor growth is monitored by in vivo imaging system.
Overview
This study demonstrates the use of orthotopic animal models to better replicate human ovarian cancer, enhancing our understanding of cancer progression and therapeutic responses. The methodology involves injecting luciferase-expressing ovarian tumor cells into the mouse bursa and monitoring tumor growth through in vivo imaging.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Animal Models
Background
- Orthotopic models provide a more accurate representation of human cancer.
- These models allow for direct observation of tumor behavior and treatment effects.
- Human ovarian cancer cells are used to enhance relevance to human disease.
- Monitoring tumor growth through bioluminescence is a key technique.
Purpose of Study
- To improve understanding of ovarian cancer progression.
- To evaluate the efficacy of therapeutic drugs in a relevant model.
- To utilize bioluminescence for tracking tumor dynamics.
Methods Used
- Intrabursal injection of luciferase-expressing ovarian tumor cells in mice.
- Oral gavage for drug administration.
- In vivo imaging to monitor tumor growth and response.
- Surgical procedures conducted under aseptic conditions.
Main Results
- Bioluminescent signals effectively tracked tumor growth and spread.
- Injected tumor cells remained localized or spread to the peritoneal cavity.
- Orthotopic models provided insights into metastatic behavior.
- Therapeutic responses were observed and documented.
Conclusions
- Orthotopic models are superior for studying human ovarian cancer.
- These models enhance the understanding of tumor biology and treatment responses.
- Future studies can build on these findings to improve therapeutic strategies.
Frequently Asked Questions
What is an orthotopic animal model?
An orthotopic animal model is one where tumor cells are implanted in the same location as they occur in humans, providing a more accurate representation of disease.
How are tumor growth and response monitored?
Tumor growth and response are monitored using bioluminescence imaging, which allows for real-time tracking of tumor dynamics.
What is the significance of using luciferase-expressing cells?
Luciferase-expressing cells emit light when a substrate is administered, enabling researchers to visualize and quantify tumor growth non-invasively.
What are the advantages of oral gavage for drug administration?
Oral gavage allows for precise dosing and direct delivery of therapeutic agents to the stomach, facilitating better absorption and efficacy.
What precautions are taken during surgical procedures?
All surgical procedures are performed under aseptic conditions to minimize the risk of infection and ensure animal welfare.
Executive Industry Relevance
Orthotopic ovarian cancer models improve preclinical predictivity by replicating human tumor microenvironment and metastatic patterns. In vivo bioluminescence imaging enables longitudinal, non-invasive monitoring of tumor burden and therapeutic response. This approach supports mechanistic de-risking and translational biomarker alignment in ovarian cancer drug discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses in a physiologically relevant ovarian tumor microenvironment.
- Operational Value: Enables functional target validation through spatial and temporal tracking of tumor cell behavior.
- Predictive Value: Supports portfolio triage by modeling human-like tumor growth, distribution, and regression patterns.
Screening & Assay Development
- Scientific Value: Prepares validated orthotopic models for reproducible compound screening in disease-relevant systems.
- Operational Value: Standardizes tumor engraftment and imaging readouts for scalable preclinical assay development.
- Translational Value: Generates quantitative bioluminescence outputs suitable for dose-response and efficacy assessments.
Translational & Preclinical Research
- Scientific Value: Models metastatic spread to peritoneal cavity, aligning with clinical ovarian cancer progression.
- Operational Value: Facilitates continuity from discovery through preclinical validation using consistent imaging endpoints.
- Risk Mitigation: Informs risk-adjusted advancement decisions by capturing therapeutic effects on primary and metastatic lesions.
Pipeline & Workflow Integration
The method integrates orthotopic modeling, oral drug delivery, and longitudinal imaging to support discovery-to-preclinical workflows in ovarian cancer research.
- Discovery Biology: Supports hypothesis testing and pathway clarification in a clinically relevant tumor microenvironment.
- Screening: Enables assay readiness through standardized tumor implantation and reproducible bioluminescence detection.
- Analytics: Provides quantitative tumor burden measurements over time to compare therapeutic conditions.
- Translational Research: Connects to preclinical continuity via orthotopic tumor growth and metastatic patterns mirroring human disease.
- Enterprise Reuse: Establishes a reusable platform for ovarian cancer target validation and therapeutic screening.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence by reducing mechanistic ambiguity in ovarian tumor biology.
- Operational Value: Delivers standardization, reproducibility, and scalability in orthotopic model generation and imaging.
- Strategic Value: Improves go/no-go decisions through longitudinal monitoring of tumor regression and metastatic spread.
- Portfolio Impact: Enables risk-adjusted prioritization based on therapeutic effects in clinically relevant models.
Implementation Considerations
- Requires expertise in murine surgical techniques and aseptic procedures for intrabursal tumor cell injection.
- Depends on bioluminescence imaging infrastructure and Luciferin substrate availability for longitudinal monitoring.
- Necessitates cross-team standardization of oral gavage dosing and imaging protocols across study sites.
- Involves adaptation considerations for different ovarian cancer cell lines and luciferase reporters.
- Limited by surgical complexity and need for dual-operator coordination during tumor implantation.
Biopharma FAQs
Why does bioluminescence imaging matter for target validation?
Bioluminescence imaging enables non-invasive, longitudinal monitoring of tumor growth and regression in live animals, providing quantitative readouts that support mechanistic target validation in orthotopic ovarian cancer models.
How does intrabursal tumor cell injection fit the ovarian cancer discovery pipeline?
Intrabursal injection places luciferase-expressing ovarian tumor cells in the anatomically correct bursa, enabling orthotopic engraftment that models human tumor localization and early metastatic spread for target validation.
What quantitative measurements does in vivo imaging enable for therapeutic assessment?
In vivo imaging provides longitudinal bioluminescence signal intensity measurements that quantify tumor burden, distribution, and response to therapeutic agents over time in individual animals.
Why are replication requirements important for cross-functional collaboration in ovarian cancer models?
Replication ensures consistent tumor engraftment and bioluminescence signal generation across animals and studies, enabling reliable data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementing longitudinal tumor imaging?
Implementation requires statistical frameworks to analyze repeated bioluminescence measurements over time, enabling comparison of tumor growth kinetics and therapeutic response across treatment groups.
